drugset / Trial / NCT05253833
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
Timeline
- Start
- 2022-08-12
- Primary completion
- 2024-08-13
- Completion
- 2024-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR882 | Unknown | — | Oral |
| Subject | Allopurinol | Small molecule | — | — |